- Home
- ROIV vs CFR Comparison
ROIV vs CFR Comparison
Compare ROIV & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | CFR |
|---|---|---|
| Founded | 2014 | 1868 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 8.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | CFR |
|---|---|---|
| Price | $21.60 | $134.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 14 |
| Target Price | $24.31 | ★ $137.64 |
| AVG Volume (30 Days) | ★ 8.2M | 418.5K |
| Earning Date | 02-09-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.99% |
| EPS Growth | N/A | ★ 20.47 |
| EPS | N/A | ★ 9.72 |
| Revenue | $20,329,000.00 | ★ $2,141,575,000.00 |
| Revenue This Year | N/A | $14.17 |
| Revenue Next Year | $741.42 | $4.47 |
| P/E Ratio | ★ N/A | $13.75 |
| Revenue Growth | N/A | ★ 9.02 |
| 52 Week Low | $8.73 | $100.31 |
| 52 Week High | $23.47 | $146.44 |
Technical Indicators
Market Signals| Indicator | ROIV | CFR |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 70.45 |
| Support Level | $20.78 | $125.03 |
| Resistance Level | $22.21 | $129.17 |
| Average True Range (ATR) | 0.69 | 2.35 |
| MACD | -0.17 | 0.38 |
| Stochastic Oscillator | 30.46 | 96.23 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.